8-K: Enzon Pharmaceuticals Enacts 1-for-100 Reverse Stock Split

Enzon Pharmaceuticals, Inc. announced a 1-for-100 reverse stock split effective March 24, 2026, and extended its Section 382 Rights Agreement to March 26, 2026, in preparation for its merger with Viskase Companies, Inc.

Summary

• Enzon Pharmaceuticals, Inc. (the Company) entered into the Eleventh Amendment to the Section 382 Rights Agreement on March 23, 2026, extending the Final Expiration Date from March 24, 2026, to noon, New York City time, on March 26, 2026.
• The extension of the Rights Agreement is deemed by management to be in the best interests of the Company and its stockholders.
• A 1-for-100 reverse stock split will become effective at 4:30 p.m., Eastern Time, on March 24, 2026.
• Common stock is expected to begin trading on a reverse stock split-adjusted basis on the OTCQB at market open on March 25, 2026, under the temporary symbol ENZND for 20 trading days.
• No fractional shares will be issued; stockholders entitled to fractional shares will receive a proportional cash payment.
• The reverse stock split is required prior to the completion of the contemplated merger between Enzon's wholly-owned subsidiary and Viskase Companies, Inc.
• The reverse stock split also makes authorized shares available for the exchange offer of Series C Non-Convertible Redeemable Preferred Stock for common stock.
• The exchange offer is expected to expire at 5:00 p.m., Eastern Time, on March 24, 2026, with the merger closing as soon as practicable thereafter.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-slightly-positive development, as it represents necessary procedural steps (reverse split, rights agreement extension) to advance a strategic merger and exchange offer, indicating progress towards a defined corporate action rather than unexpected operational news.

Positives

• The reverse stock split facilitates the completion of the merger with Viskase Companies, Inc.
• The reverse stock split also enables the issuance of common stock related to the outstanding exchange offer for Series C Preferred Stock.
• Management believes extending the Section 382 Rights Agreement is in the best interests of the Company and its stockholders.

Negatives

• A reverse stock split often indicates a low share price and can sometimes be perceived negatively by investors, though here it's for a specific strategic purpose (merger).
• The repeated, short-term extensions of the Section 382 Rights Agreement (this is the eleventh amendment) could suggest ongoing uncertainty or delays in the underlying strategic process it is meant to protect.

Risks

• The risk that the conditions to the closing of the proposed transaction (merger with Viskase) are not satisfied, including failure to obtain necessary approvals.
• Uncertainties regarding the timing of the consummation of the proposed transactions, including satisfaction of closing conditions.
• The ability of Viskase to timely deliver financial statements required by the Merger Agreement.
• The possibility that other anticipated benefits of the proposed transaction, such as revenues, expenses, earnings, growth, and tax treatment, will not be realized.
• Potential litigation related to the proposed transaction against Enzon, Viskase, or their officers/directors.
• Possible disruptions from the proposed transaction that could harm Enzon's or Viskase's respective businesses.
• The ability of Viskase to retain, attract, and hire key personnel.
• Potential adverse reactions or changes to relationships with customers, employees, suppliers, or other parties resulting from the announcement or completion of the proposed transaction.
• Potential business uncertainty, including changes to existing business relationships, during the pendency of the proposed transaction that could affect financial performance.
• Certain restrictions during the pendency of the proposed transaction that may impact the ability to pursue certain business opportunities or strategic transactions.
• Uncertainty regarding the exchange ratio and relative ownership levels as of the closing of the transactions.
• Estimates regarding future revenue, expenses, and capital requirements following the closing of the transactions.
• Legislative, regulatory, and economic developments.
• Unpredictability and severity of catastrophic events, including terrorism, trade wars, or war/hostilities.

Future Outlook

The reverse stock split and rights agreement extension are critical steps towards the anticipated closing of the merger with Viskase Companies, Inc. and the completion of an exchange offer for Series C Preferred Stock. The combined company's common stock is expected to trade on the OTCQB.

Management Comments

• Management believes that it is in the best interests of the Company and its stockholders to provide for a Final Expiration Date of noon, New York City time, on March 26, 2026, as established in the Eleventh Amendment.
• The reverse stock split was completed to make available authorized shares of common stock needed in connection with the anticipated closing of the previously announced merger with Viskase Companies, Inc., and the related issuances of common stock to be made in connection with the Company’s outstanding exchange offer providing for the exchange of the Company’s Series C Non-Convertible Redeemable Preferred Stock for shares of the Company’s common stock.

Industry Context

StockSavvy.ai notes that reverse stock splits are common in the biotechnology and pharmaceutical sectors, particularly for smaller companies seeking to meet listing requirements or facilitate strategic transactions like mergers. The repeated extensions of the Section 382 Rights Agreement suggest a complex or prolonged M&A process, which is not uncommon in the highly regulated pharma industry.

Comparison to Industry Standards

• Reverse stock splits, such as Enzon's 1-for-100, are frequently utilized by companies, particularly those on OTC markets, to increase per-share price to meet exchange listing requirements or to make shares more attractive to institutional investors. For example, similar actions have been taken by companies like Aeterna Zentaris Inc. (AEZS) or Sorrento Therapeutics, Inc. (SRNEQ) in the past to maintain compliance or facilitate corporate restructuring.
• Section 382 Rights Agreements (poison pills) are standard corporate governance tools used to protect net operating loss (NOL) carryforwards from being limited by changes in ownership, which is a common concern for companies with a history of losses, often seen in early-stage biotech. The frequent amendments to Enzon's agreement, however, suggest a dynamic and potentially drawn-out process leading up to the Viskase merger, contrasting with more stable, long-term poison pill implementations seen in larger, more established firms.

Corporate Governance

Stakeholder Impact

• Shareholders: Will see their number of shares reduced by a factor of 100, with a proportional increase in share price. Those holding fractional shares will receive cash. The action is intended to facilitate a merger, potentially leading to a stronger combined entity. The extension of the Rights Agreement aims to protect their tax benefits.
• Employees: No direct impact mentioned, but the merger could bring future changes.
• Customers/Suppliers/Creditors: No direct impact mentioned in this filing.

Next Steps

• Common stock expected to begin trading on a reverse stock split-adjusted basis on the OTCQB at market open on March 25, 2026.
• Common stock expected to trade under the temporary symbol ENZND for 20 trading days.
• Expiration of the exchange offer is expected to occur at 5:00 p.m., Eastern Time, on March 24, 2026.
• Closing of the merger with Viskase Companies, Inc. is expected to occur as soon as practicable after the exchange offer expiration.

Key Dates

Recommendation

The filing details procedural steps (reverse stock split, rights agreement extension) necessary for an anticipated merger and exchange offer. These actions are expected and pre-approved, indicating progress towards a strategic transaction rather than new operational performance. While a reverse split can sometimes signal underlying issues, here it's explicitly tied to facilitating a merger, which could be beneficial long-term. However, the repeated, short-term extensions of the rights agreement suggest ongoing complexities. Investors should hold as the company navigates these final steps towards the merger, awaiting the outcome of the combined entity.

Keywords

Enzon Pharmaceuticals, Reverse Stock Split, Section 382 Rights Agreement, Merger, Viskase Companies, Corporate Governance, Stock Exchange, OTCQB, Preferred Stock Exchange Offer, Pharmaceuticals, Biotech, Corporate Action